Advertisement

Vitiligo

      Abstract

      The destruction of melanocytes is the cause of depigmented maculae that clinically represent the disease vitiligo . Although the cause is unknown, various theories such as the autoimmune, autocytotoxic, and neural hypotheses have been proposed. Extensive research has provided numerous answers regarding the pathogenesis, histopathologic evidence, and treatment of vitiligo. This discussion of vitiligo summarizes the varied clinical presentations of the disease, theories attempting to explain the mechanism of melanocyte destruction, histopathologic findings, and different treatment modalities currently available. (J Am Acad Dermatol 1998;38:647-66.) Learning Objective: At the conclusion of this learning activity, participants should be familiar with the clinical and histopathologic presentations of vitiligo, the etiologic hypotheses of the disease, and the treatment options.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Carter R
        A dictionary of dermatologic terms.
        Williams & Wilkins, Baltimore (MD)1992
        • Fitzpatrick TB
        Hypomelanosis.
        South Med J. 1964; 57: 995-1005
        • Nair BK
        Vitiligo: a retrospect.
        Int J Dermatol. 1978; 17: 755-757
        • Singh G
        • Ansari Z
        • Dwivedi R
        Vitiligo in ancient Indian medicine.
        Arch Dermatol. 1974; 109: 913
        • Sharque KE
        Vitiligo.
        Clin Exp Dermatol. 1984; 9: 117-126
        • Lerner A
        Vitiligo.
        J Invest Dermatol. 1959; 32: 285-310
        • Majumder P
        • Nordlund J
        • Nath S
        Pattern of familial aggregation of vitiligo.
        Arch Dermatol. 1993; 129: 994-998
        • Majumder P
        • Das S
        • Li C
        A genetical model for vitiligo.
        Am J Hum Genet. 1988; 43: 119-125
        • Das S
        • Majumder P
        • Chakraborty R
        • et al.
        Studies on vitiligo: epidemiological profile in Calcutta, India.
        Genet Epidemiol. 1985; 2: 71-78
        • Lerner A
        On the etiology of vitiligo and gray hair.
        Am J Med. 1971; 51: 141-147
        • Howitz J
        • Brodthage H
        • Schwartz M
        • Thomsen K
        Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark.
        Arch Dermatol. 1977; 113: 47-52
        • Mehta N
        • Shah K
        • Theodore C
        • Vyas V
        • Patel A
        Epidermiologic study of vitiligo in Surat area, South Gujarat.
        Indian J Med Res. 1973; 61: 145-154
        • Fitzpatrick T
        • Szabo G
        The melanocyte: cytology and cytochemistry.
        J Invest Dermatol. 1959; 32: 197-209
        • Goldgeier M
        • Klein L
        • Klein-Angerer S
        • et al.
        The distribution of melanocytes in the leptomeninges of the human brain.
        J Invest Dermatol. 1984; 82: 235
        • Elliott J
        Clinical experiences with methosxalen in the treatment of vitiligo.
        J Invest Dermatol. 1959; 32: 311-314
        • Lerner A
        • Nordlund J
        Vitiligo: What is it? Is it important?.
        JAMA. 1978; 239: 1183-1187
        • Fitzpatrick TB
        • Parrish JA
        • Pathak MA
        Phototherapy of vitiligo (idiopathic leukoderma).
        in: Sunlight and man: normal and abnormal photobiologic responses. University of Tokyo Press, Tokyo1974: 783-792
        • Janniger CK
        Childhood vitiligo.
        Cutis. 1993; 51: 25-28
        • Koga M
        Vitiligo: a new classification and therapy.
        Br J Dermatol. 1977; 97: 255-261
        • Hann SK
        • Lee HJ
        Segmental vitiligo: clinical findings in 208 patients.
        J Am Acad Dermatol. 1996; 35: 671-674
        • Hann SK
        • Chung HS
        • Dark YK
        Epidemiologic case control study in patients with vitiligo [letter].
        J Am Acad Dermatol. 1997; 36: 282-283
        • Ortonne JP
        • Mosher DB
        • Fitzpatrick TB
        Vitiligo and other hypomelanoses of hair and skin.
        in: Plenum Medical Book Company, New York1983: 172-176
        • Pinkus H
        Vitiligo: What is it?.
        J Invest Dermatol. 1959; 32: 281-284
        • Lerner AB
        • Cage G
        Melanomas in horses.
        Yale J Biol Med. 1973; 46: 646-649
        • Powell FC
        • Dicken CH
        Psoriasis and vitiligo.
        Acta Derm Venereol (Stockh). 1983; 63: 246-249
        • Sidi E
        • Bourgeois-Gavardin J
        Vitiligo revele par une dermite artificielle.
        Bull Soc Fr Dermatol Syph. 1951; 58: 492-493
        • Boersma BR
        • Westerhof W
        • Bos JD
        Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients.
        J Am Acad Dermatol. 1995; 33: 990-995
        • Levine EL
        • Ribeiro GG
        Vitiligo and radiotherapy: the Koebner phenomenon demonstrated in patients with vitiligo undergoing radiotherapy for carcinoma of the breast.
        Clin Oncol. 1994; 6: 133-134
        • Papadavid E
        • Yu RC
        • Munn S
        • et al.
        Strict anatomical coexistance of vitiligo and psoriasis vulgaris: A Koebner phenomenon?.
        Clin Exp Dermatol. 1996; 21: 138-140
        • Koo SW
        • Suh CO
        • Hann SK
        Vitiligo following radiotherapy for carcinoma of the breast.
        Br J Dermatol. 1996; 135: 852-853
        • Riordan AT
        • Nahass GT
        Occupational vitiligo following allergic contact dermatitis.
        Contact Dermatitis. 1996; 34: 371
        • Mancusco G
        • Reggiani M
        • Berdondini RM
        Occupational dermatitis in shoemakers.
        Contact Dermatitis. 1996; 34: 17-22
        • Selvaag E
        Chloroquine-induced vitiligo.
        Acta Derm Venereol (Stockh). 1996; 76: 166-167
        • Brown-Harrell V
        • Nitta AT
        • Goble M
        Apparent exacerbation of vitiligo syndrome in a patient with pulmonary Mycobacterium avium complex disease who received clofazimine therapy.
        Clin Infect Dis. 1996; 22: 581-582
        • Kawakami Y
        • Robbins PF
        • Rosenberg SA
        Human melanoma antigens recognized by T lymphocytes.
        Keio J Med. 1996; 45: 100-108
        • Lerner A
        • Kirkwood J
        Vitiligo and melanoma: Can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family?.
        J Am Acad Dermatol. 1984; 11: 696-701
        • Millikan L
        • Hook R
        • Manning P
        Gross and ultrastructural studies in a new melanoma model: the Sinclair swine.
        Yale J Biol Med. 1973; 46: 631-645
        • Misfeldt ML
        • Grimm DR
        Sinclair miniature swine: an animal model of human melanoma.
        Vet Immunol Immunopathol. 1994; 43: 167-175
        • Cui J
        • Chen D
        • Misfeldt ML
        • et al.
        Antimelanoma antibodies in swine with spontaneously regressing melanoma.
        Pigment Cell Res. 1995; 8: 60-63
        • Merimsky O
        • Shoenfeld Y
        • Baharav F
        • et al.
        Melanoma-associated hypopigmentation: Where are the antibodies?.
        Am J Clin Oncol. 1996; 19: 613-618
        • Milton G
        • McCarthy W
        • Carlton A
        Malignant melanoma and vitiligo.
        Aust J Derm. 1971; 12: 131-142
        • Bystryn J
        Serum antibodies in vitiligo patients.
        Clin Dermatol. 1989; 7: 136-145
        • Nordlund J
        • Kirkwood M
        • Forget B
        • et al.
        Vitiligo in patients with metastatic melanoma: a good prognostic sign.
        J Am Acad Dermatol. 1983; 9: 689-696
        • Koh H
        • Sober A
        • Nakagawa H
        • et al.
        Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study.
        J Am Acad Dermatol. 1983; 9: 696-708
        • Balabanov K
        • Andreev VC
        • Tchernozemski I
        Malignant melanoma and vitiligo.
        Dermatologica. 1968; 139: 211-219
        • Cavallari V
        • Cannavo SP
        • Ussia AF
        • et al.
        Vitiligo associated with metastatic malignant melanoma.
        Int J Dermatol. 1996; 35: 738-739
        • Berd D
        • Mastrangelo MJ
        • Lattime E
        • et al.
        Melanoma and vitiligo: immunology’s Grecian urn.
        Cancer Immunol Immunother. 1996; 42: 263-267
        • Merimsky O
        • Shoenfeld Y
        • Yecheskel G
        • et al.
        Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.
        Cancer Immunol Immunother. 1994; 38: 411-416
        • Ortonne JP
        • Perrot H
        Giant melanin granules in vitiliginous achromia with malignant melanoma.
        Acta Derm Venereol (Stockh). 1978; 58: 475-480
        • Uehara M
        • Miyauchi H
        • Tanaka S
        Diminished contact sensitivity response in vitiliginous skin.
        Arch Dermatol. 1984; 120: 195-198
        • Hatchome N
        • Aiba S
        • Kato T
        • et al.
        Possible functional impairment of Langerhans’ cells in vitiliginous skin.
        Arch Dermatol. 1987; 123: 51-54
        • Nordlund J
        • Forget B
        • Kirkwood J
        • et al.
        Dermatitis induced by applications of monobenzone in patients with active vitiligo.
        Arch Dermatol. 1985; 121: 1141-1144
        • Porter J
        • Beuf A
        • Nordlund J
        • et al.
        Psychological reaction to chronic skin disorders.
        Gen Hosp Psychiatry. 1979; 1: 73-77
        • Porter JR
        • Beuf AH
        • Lerner AB
        • et al.
        The effect of vitiligo on sexual relationships.
        J Am Acad Dermatol. 1990; 22: 221-222
        • Porter JR
        • Beuf AH
        • Lerner A
        • et al.
        Psychosocial effect of vitiligo: a comparison of vitiligo patients with “normal” control subjects, with psoriasis patients, and with patients with other pigmentary disorders.
        J Am Acad Dermatol. 1986; 15: 220-224
        • Kent G
        • Al’Abadie M
        Psychologic effects of vitiligo: a critical incident analysis.
        J Am Acad Dermatol. 1996; 35: 895-898
        • Betterle C
        • Caretto A
        • De Zio A
        • et al.
        Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo.
        Dermatologica. 1985; 171: 419-423
        • Betterle C
        • Del Prete G
        • Peserico A
        • et al.
        Autoantibodies in vitiligo.
        Arch Dermatol. 1976; 112: 1328
        • Butterworth T
        • Strean L
        Clinical genodermatology.
        in: Williams & Wilkins, Baltimore (MD)1962: 4-6
        • Burns-Cox C
        • Pearson J
        Addison’s disease, vitiligo and multiple autoantibodies.
        Postgrad Med J. 1972; 48: 115-117
        • Fields J
        • Fragola L
        • Hadley T
        Hypoparathyroidism, candidiasis, alopecia and vitiligo.
        Arch Dermatol. 1971; 103: 687-690
        • Fisher M
        • Fitzpatrick T
        Candidiasis, vitiligo, Addison’s disease, and hypoparathyroidism.
        Arch Dermatol. 1970; 102: 110-112
        • Forcier R
        • McIntyre O
        • Frey W
        Autoimmunity and multiple endocrine abnormalities.
        Arch Intern Med. 1972; 129: 638-641
        • Koga M
        • Tango T
        Clinical features and course of type A and type B vitiligo.
        Br J Dermatol. 1988; 118: 223-228
        • Bird SJ
        • Brown MJ
        • Shy ME
        • Scherer SS
        Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma.
        Neurology. 1996; 46: 822-824
        • Cunliffe W
        • Hall R
        • Newell J
        • et al.
        Vitiligo, thyroid disease and autoimmunity.
        Br J Dermatol. 1968; 80: 135-139
        • Schallreuter KU
        • Lemke R
        • Brandt O
        • et al.
        Vitiligo and other diseases: Coexistence or true association?.
        Dermatology. 1994; 188: 269-275
        • Koshiyama H
        • Ito M
        • Yoshinami N
        • et al.
        Two cases of asymptomatic adrenocortical insufficiency with autoimmune thyroid disease.
        Endocr J. 1994; 41: 373-378
        • Dunlop D
        Eighty-six cases of Addisons disease.
        Br Med J. 1963; 2: 887-891
        • Meecham J
        • Jones E
        Addisons disease and Addisonian anaemia.
        Lancet. 1967; 1: 535-538
        • Allison J
        • Curtis A
        Vitiligo and pernicious anaemia.
        Arch Dermatol. 1955; 72: 407
        • Grunnet I
        • Howitz J
        Vitiligo and pernicious anemia.
        Arch Dermatol. 1970; 101: 82-85
        • Dawber R
        Integumentary associations of pernicious anemia.
        Br J Dermatol. 1969; 82: 221-222
        • Harrakati MSE
        Pernicious anemia in Arabs.
        Blood Cells Mol Dis. 1996; 22: 98-103
        • Dawber R
        Vitiligo in mature-onset diabetes mellitus.
        Br J Dermatol. 1968; 80: 275-278
        • Husebye ES
        • Gebre-Medhin G
        • Tuomi T
        • et al.
        Autoantibodies against aromatic L-amino and decarboxylase in autoimmune polyendocrine syndrome type 1.
        J Clin Endocrinol Metab. 1997; 82: 147-150
        • Cecchi R
        • Giomi A
        • Tuci F
        • et al.
        Pityriasis rubra pilaris, lichen planus, alopecia universalis and vitiligo in a patient with chronic viral hepatitis C.
        Dermatology. 1994; 188: 239-240
        • Sharma VK
        • Kumar V
        • Dawn G
        A clinical study of childhood alopecia areata in Chandigarh, India.
        Pediatr Dermatol. 1996; 13: 372-377
        • Sharma VK
        • Dawn G
        • Kumar B
        Profile of alopecia areata in Northern India.
        Int J Dermatol. 1996; 35: 22-27
        • Mandry RC
        • Ortiz LJ
        • Lugo-Somolinos A
        • et al.
        Organ-specific autoantibodies in vitiligo patients and their relatives.
        Int J Dermatol. 1996; 35: 18-21
        • Albert D
        • Nordlund J
        • Lerner A
        Ocular abnormalities occurring with vitiligo.
        Ophthalmology. 1979; 86: 1145-1158
        • Cowan C
        • Halder R
        • Grimes P
        • et al.
        Ocular disturbances in vitiligo.
        J Am Acad Dermatol. 1986; 15: 17-24
        • Albert D
        • Wagoner M
        • Pruett R
        • et al.
        Vitiligo and disorders of the retinal pigment epithelium.
        Br J 0phthalmol. 1983; 67: 153-156
        • Wagoner M
        • Albert D
        • Lerner A
        • et al.
        New observations on vitiligo and ocular disease.
        Am J Ophthalmol. 1983; 96: 16-26
        • Wolff D
        Melanin in the inner ear.
        Arch Otolaryngol. 1931; 14: 195-211
        • Tosti A
        • Bardazzi F
        • Tosti G
        • et al.
        Audiologic abnormalities in cases of vitiligo.
        J Am Acad Dermatol. 1987; 17: 230-233
        • Thurmon T
        • Jackson J
        • Fowler C
        Deafness and vitiligo.
        Birth Defects. 1976; 12: 315-320
        • Tosti A
        • Bardazzi F
        • De Padova M
        • et al.
        Deafness and vitiligo in an Italian family.
        Dermatologica. 1986; 172: 178-179
        • Vogt A
        Fruhzeitiges ergrauen der Zilien und Bemerkungen uber den sogenannten Plotlzichen eintritt dieser Veranderung.
        Klin Monatsbl Augenheilkd. 1906; 4: 228-242
        • Harada E
        Beitrag zur klinischen kenntnis von michteitriger choroiditis (choroiditis diffusa acta).
        Acta Soc Ophthalmol Jpn. 1926; 30: 356-378
        • Koyanagi Y
        Dysakusis, alopecia and poliosis beischwerer uveitis nicht traumatischen ursprungs.
        Klin Monatsbl Augenheilkd. 1929; 82: 194-211
        • Nordlund J
        • Albert D
        • Forget B
        • et al.
        Halo nevi and the Vogt-Koyanagi-Harada syndrome.
        Arch Dermatol. 1980; 116: 690-692
        • Barnes L
        Vitiligo and the Vogt-Koyanagi-Harada syndrome.
        Dermatol Clin. 1988; 6: 229-239
        • Weber SW
        • Kazdan JJ
        The Vogt-Koyanagi-Harada syndrome in children.
        J Pediatric Ophthalmol. 1977; 14: 96-99
        • Moorthy RS
        • Inomata H
        • Rao NA
        Vogt-Koyanagi-Harada Syndrome.
        Surv Ophthalmol. 1995; 39: 265-292
        • Yakura H
        • Wakisaka A
        • Aizawa M
        • et al.
        HLA-D antigen of Japanese origin (LD-Wa) and its association with Vogt-Koyanagi-Harada syndrome.
        Tissue Antigens. 1976; 8: 35-42
        • Martinez JA
        • Lopez PF
        • Sternberg P
        • et al.
        Vogt-Koyanagi-Harada syndrome in patients with Cherokee Indian ancestry.
        Am J Ophthalmol. 1992; 114: 615-620
        • Majumder P
        • Nordlund J
        • Nath S
        Pattern of familial aggregation of vitiligo.
        Arch Dermatol. 1993; 129: 994-998
        • Venkataram MN
        • White AG
        • Leeny WA
        • et al.
        HLA antigens in Omani patients with vitiligo.
        Clin Exp Dermatol. 1995; 20: 35-37
        • Hafez M
        • Sharaf L
        • Abdel-Nabi S
        The genetics of vitiligo.
        Acta Derm Venereol (Stockh). 1983; 63: 249-251
        • Al-Fouzan A
        • Al-Arbash M
        • Fouad F
        • et al.
        Study of HLA class I/II and T lymphocyte subsets in Kuwaiti vitiligo patients.
        Eur J Immunogenet. 1995; 22: 209-213
        • Nath SK
        • Majumder PP
        • Nordlund JJ
        Genetic epidemiology of vitiligo: multilocus recessivity crossvalidated.
        Am J Hum Genet. 1994; 55: 981-990
        • Merelender J
        • Rywlin J
        Hereditary of acquired vitiligo (vitiligo in three generations).
        Acta Derm Venereol (Stockh). 1940; 21: 583-585
        • Mohr J
        Vitiligo in a pair of monovular twins.
        Acta Genet Stat Med. 1951; 2: 252-255
        • Siemens HW
        Die zwillingspathologie der vitiligo.
        Acta Genet Med Gemellol (Roma). 1953; 2: 118-124
        • Hertz D
        • Gazze L
        • Kirkpatrick C
        • et al.
        Autoimmune vitiligo.
        N Engl J Med. 1977; 297: 634-637
        • Howanitz N
        • Nordlund J
        • Lerner A
        • et al.
        Antibodies to melanocytes.
        Arch Dermatol. 1981; 117: 705-708
        • Aronson P
        • Hashimoto K
        Association of IgA antimelanoma antibodies in the sera of vitiligo patients with active disease.
        J Invest Dermatol. 1987; 88: 475
        • Norris D
        • Kissinger M
        • Naughton G
        • et al.
        Evidence for immunologic mechanisms in human vitiligo: patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.
        J Invest Dermatol. 1988; 90: 783-789
        • Bi C
        • Suanders J
        • Soltani K
        • et al.
        Anti-melanocyte autoantibodies and vitiligo.
        J Invest Dermatol. 1989; 92: 403
        • D’Amelio R
        • Frati C
        • Fattorossi A
        • et al.
        Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives.
        Ann Allergy. 1990; 65: 143-145
        • Lorini R
        • Orecchia G
        • Martinett M
        • et al.
        Autoimmunity in vitiligo: relationship with HLA, Gm and Km polymorphisms.
        Autoimmunity. 1992; 11: 255-260
        • Austin L
        • Boissy R
        • Jacobson B
        • et al.
        The detection of melanocyte autoantibodies in the Smyth chicken model for vitiligo.
        Clin Immunol Immunopathol. 1992; 64: 112-120
        • Zaman T
        • Begum S
        • Waheed M
        In vitro assessment of ‘T’ lymphocyte functioning in vitiligo.
        Acta Derm Venereol (Stockh). 1992; 72: 2667
        • Yu J
        • Kao C
        • Yu C
        Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with nonsegmental-type vitiligo.
        J Invest Dermatol. 1993; 100: 823-828
        • Yamamoto T
        • Yokoyama A
        T cell receptor Vβ repertoire subsets in psoriasis vulagaris and vitiligo.
        Int J Dermatol. 1996; 35: 151
        • Naughton G
        • Eisinger M
        • Bystryn J
        Antibodies to normal human melanocytes in vitiligo.
        J Exp Med. 1983; 158: 246-251
        • Naughton G
        • Eisinger M
        • Bystryn J
        Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation.
        J Invest Dermatol. 1983; 81: 540-542
        • Naughton G
        • Reggiardo D
        • Bystryn J
        Correlation between vitiligo antibodies and extent of depigmentation in vitiligo.
        J Am Acad Dermatol. 1986; 15: 978-981
        • Cui J
        • Arita Y
        • Eisinger N
        • et al.
        Characterization of vitiligo antigens.
        J Invest Dermatol. 1992; 98: 600
        • Cui J
        • Harning R
        • Henn M
        • et al.
        Identification of pigment cell antigens defined by vitiligo antibodies.
        J Invest Dermatol. 1992; 98: 162-165
        • Harning R
        • Cui J
        • Bystryn J
        Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo.
        J Invest Dermatol. 1991; 97: 1078-1080
        • Cui J
        • Arita Y
        • Bystryn JC
        Characterization of vitiligo antigens.
        Pigment Cell Res. 1995; 8: 53-59
        • Park YK
        • Kim NS
        • Hann SK
        • et al.
        Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients.
        J Dermatol Sci. 1996; 11: 111-120
        • Baharav E
        • Merimski O
        • Shoenfeld Y
        • et al.
        Tyrosinase as an autoantigen in patients with vitiligo.
        Clin Exp Immunol. 1996; 105: 84-88
        • Merimsky O
        • Baharav E
        • Shoenfeld Y
        • et al.
        Anti-tyrosinase antibodies in malignant melanoma.
        Cancer Immunol Immunother. 1996; 42: 297-302
        • Hammer H
        Lymphocyte transformation test in sympathetic ophthalmitis and the Vogt-Koyanagi-Harada syndrome.
        Br J Ophthal. 1971; 55: 850-852
        • Hammer H
        Cellular hypersensitivity to uveal pigment confirmed by leucocyte migration tests in sympathetic ophthalmitis and the Vogt-Koyanagi-Harada syndrome.
        Br J Ophthal. 1974; 59: 773-776
        • Wojdani A
        • Grimes P
        • Loeb L
        • et al.
        Detection of antibenzene ring antibodies in patients with vitiligo.
        J Invest Dermatol. 1992; 98: 644
        • Xia P
        • Geoghegan W
        • Jordan R
        Vitiligo antibodies: studies of subclass distribution and complement activation.
        J Invest Dermatol. 1991; 96: 627
        • Stites DP
        Clinical laboratory methods for detection of cellular immunity.
        in: 8th ed. Basic & clinical immunology. Appleton & Lange, Norwalk (CT)1994: 199
        • Soubiran P
        • Benzaken S
        • Bellet C
        • et al.
        Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies.
        Br J Dermatol. 1985; 113: 124-127
        • Grimes P
        • Ghoneum M
        • Stockton T
        • et al.
        T-cell profiles in vitiligo.
        J Am Acad Dermatol. 1986; 14: 196
        • Halder R
        • Walters C
        • Jonson B
        • et al.
        Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study.
        J Am Acad Dermatol. 1986; 14: 733
        • Mozzanica N
        • Frigerio U
        • Finzi A
        • et al.
        T cell subpopulations in vitiligo: a chronobiologic study.
        J Am Acad Dermatol. 1990; 22: 223-230
        • Le Poole IC
        • van der Wijngaard RM
        • Westerhof W
        • et al.
        Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance.
        Am J Pathol. 1996; 148: 1219-1228
        • Durham-Pierre DG
        • Walters CS
        • Halder RM
        • et al.
        Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo.
        J Am Acad Dermatol. 1995; 33: 26-30
        • Naughton G
        • Mahaffey M
        • Bystryn J
        Antibodies to surface antigens of pigmented cells in animals with vitiligo.
        Proc Soc Exp Biol Med. 1986; 181: 423-426
        • Sreekumar GP
        • Eft GF
        • Smyth JR
        5-Azacytidine treatment induces autoimmune vitiligo in parental control strains of the Smyth line chicken model for autoimmune vitiligo.
        Clin Immunol Immunopathol. 1996; 81: 136-144
        • Erf GF
        • Trejo-Skalli AV
        • Smyth JR
        T cells in regenerating feathers of Smyth line chickens with vitiligo.
        Clin Immunol Immunopathol. 1995; 76: 120-126
        • Erf GF
        • Smyth Jr, JR
        Alterations in blood leukocyte populations in Smyth line chickens with autoimmune vitiligo.
        Poultry Sci. 1996; 75: 351-356
        • Lamont S
        • Smyth J
        The Smyth chicken: effect of bursectomy on development of a spontaneous postnatal amelanosis.
        Clin Immunol Immunopathol. 1981; 21: 407-411
        • Searle EA
        • Boissy RE
        • Austin LM
        • et al.
        Smith chicken melanocyte autoantibodies: cross-species reactivity, in vivo binding, and plasma membrane localization of the antigen(s).
        J Invest Dermatol. 1991; 96: 631
        • Moellmann G
        • Klein-Angerer S
        • Scollay A
        • et al.
        Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo.
        J Invest Dermatol. 1982; 79: 321-330
        • Pawelek J
        • Korner A
        • Bergstrom A
        • et al.
        New regulators of melanin biosynthesis and the autodestruction of melanoma cells.
        Nature. 1980; 286: 617-619
        • Schallreuter K
        • Pittelkow M
        Defective calcium uptake in keratinocyte cell cultures from vitiliginous skin.
        Arch Dermatol Res. 1988; 280: 137-139
        • Schallreuter K
        • Pittelkow M
        • Wood J
        EF-Hands calcium binding regulates the thioredoxin reductase/thioredoxin electron transfer in human keratinocytes.
        Biochem Biophys Res Commun. 1989; 162: 1311-1316
        • Yada Y
        • Higuchi K
        • Imokawa G
        Effects of endothelins on signal transduction and proliferation in human melanocytes.
        J Biol Chem. 1991; 266: 18352-18357
        • Imokawa G
        • Yada Y
        • Miyagishi M
        Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes.
        J Biol Chem. 1992; 267: 24675-24680
        • Yohn J
        • Morelli J
        • Walchak S
        • et al.
        Cultured human keratinocytes synthesize and secrete endothelin-1.
        J Invest Dermatol. 1993; 100: 23-26
        • Schallreuter K
        • Levenig C
        Keratinocyte involvement in the pathophysiology of vitiligo.
        J Invest Dermatol. 1991; 96: 1024
        • Schallreuter K
        • Wood J
        • Berger J
        Low catalase levels in the epidermis of patients with vitiligo.
        J Invest Dermatol. 1991; 97: 1081-1085
        • Bowers RR
        • Lujan J
        • Biboso A
        • et al.
        Premature avian melanocyte death due to low antioxidant levels of protection: fowl model for vitiligo.
        Pigment Cell Res. 1994; 7: 409-418
        • Graham DG
        • Tiffany SM
        • Bell WR
        • Gutknecht WF
        Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro.
        Mol Pharmacol. 1978; 14: 644-653
        • Rotman A
        • Daly JW
        • Creveling CR
        Oxygen-dependent reaction of 6-hydroxydopamine, 5,6-dihydroxytryptamine, and related compounds with proteins in vitro: a model for cytotoxicity.
        Mol Pharmacol. 1976; 12: 887-899
        • Parsons PG
        Modification of DOPA toxicity in human tumor cells.
        Biochem Pharmacol. 1985; 34: 1801-1807
        • Laties AM
        • Lemer AB
        Iris colour and relationship of tyrosinase activity to adrenergic innervation.
        Nature. 1975; 255: 152-153
        • Chanco-Turner M
        • Lerner A
        Physiologic changes in vitiligo.
        Arch Dermatol. 1965; 91: 390-404
        • Schallreuter KU
        • Wood JM
        • Pittelkow MR
        • et al.
        Increased monoamine oxidase A activity in the epidermis of patients with vitiligo.
        Arch Dermatol Res. 1996; 288: 14-18
        • Morohashi M
        • Hashimoto K
        • Goodman T
        • Newton D
        • Rist T
        Ultrastructural studies of vitiligo, Vogt-Koyanagi syndrome, and incontinentia pigmenti achromians.
        Arch Dermatol. 1977; 113: 755-766
        • Breathnach A
        • Bor S
        • Wyllie L
        Electron microscopy of peripheral nerve terminals and marginal melanocytes in vitiligo.
        J Invest Dermatol. 1966; 47: 125-140
        • Al’Abadie M
        • Gawkrodger D
        • Senior H
        • et al.
        Neuro-ultrastructural and neuropeptide studies in vitiligo.
        Clin Exp Dermatol. 1992; 15: 284
        • Gokhale B
        • Mehta L
        Histopathology of vitiliginous skin.
        Int J Dermatol. 1983; 22: 477-480
        • Al’Abadie MS
        • Warren MA
        • Beehen SS
        Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study.
        Int J Dermatol. 1995; 34: 837-840
        • Abdel-Naser M
        • Gollnick B
        • Orfanos C
        Evidence for primary involvement of keratinocytes in vitiligo.
        Arch Dermatol Res. 1991; 283: 47
        • Abdel-Naser M
        • Kruger S
        • Krasagakis L
        • et al.
        Evidence for involvement of both cell-mediated and humoral immunity in generalized vitiligo.
        J Invest Dermatol. 1991; 96: 1024
        • Morrone A
        • Picardo M
        • De Luca C
        • et al.
        Catecholamines and vitiligo.
        Pigment Cell Res. 1992; 5: 65-69
        • Schallreuter-Wood KU
        • Wood JM
        Catecholamines in vitiligo.
        Dermatology. 1996; 192: 191-192
        • Jarrett A
        • Szabo G
        The pathological varieties of vitiligo and their response to treatment with meladinine.
        Br J Dermatol. 1956; 68: 313-326
        • Halaban R
        • Moellmann G
        White mutants in mice shedding light on humans.
        J Invest Dermatol. 1993; 100: 176S-185S
        • Norris D
        • Horikawa T
        • Morelli J
        Melanocyte destruction and repopulation in vitiligo.
        Pigment Cell Res. 1994; 7: 193-203
        • Barona MI
        • Arrunategui A
        • Falabella R
        • et al.
        An epidemiologic case-control study in a population with vitiligo.
        J Am Acad Dermatol. 1995; 33: 621-625
        • Boissy R
        • Liu Y
        • Medrano E
        • et al.
        Structural abnormalities of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients.
        J Invest Dermatol. 1991; 97: 395-404
        • Chakraborty DP
        • Roy S
        • Chakraborty AK
        Vitiligo, psoralen, and melanogenesis: some observations and understanding.
        Pigment Cell Res. 1996; 9: 107-116
        • Birbeck M
        • Breathnach A
        • Everall J
        An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cells) in vitiligo.
        J Invest Dermatol. 1961; 37: 51-64
        • Lamoreux M
        • Boissy R
        • Womack J
        • et al.
        The vit gene maps to the mi (microphthalmia) locus of the laboratory mouse.
        J Hered. 1992; 83: 435-439
        • Le Poole I
        • Wijngaard R
        • Westerhof W
        • et al.
        Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation.
        J Invest Dermatol. 1993; 100: 816-822
        • Boissy R
        • Beato K
        • Nordlund J
        Dilated rough endoplasmic reticulum and premature death in melanocytes cultured from the vitiligo mouse.
        Am J Pathol. 1991; 138: 1511-1525
        • Koranne RV
        • Sachdeva KG
        Vitiligo.
        Int J Dermatol. 1988; 27: 676-681
        • Bhawan J
        • Bhutani L
        Keratinocyte damage in vitiligo.
        J Cutan Pathol. 1983; 10: 207-212
        • Miescher G
        • Schaaf F
        La question des cellules de langerhans.
        Bull Soc Fr Derm Syph. 1935; 42: 1101-1112
        • Brown J
        • Winkelmann R
        • Wolff K
        Langerhans cells in vitiligo: a quantitative study.
        J Invest Dermatol. 1967; 49: 386-390
        • Claudy A
        • Rouchouse B
        Langerhans cells and vitiligo: quantitative study of T6 and HLA-DR antigen-expressing cells.
        Acta Derm Venereol (Stockh). 1984; 64: 334-336
        • Riley P
        Distribution of epidermal dendritic cells in pigmented and unpigmented skin.
        J Invest Dermatol. 1967; 48: 28-38
        • Mishima Y
        • Miller-Milinska A
        Junctional and high level dendritic cells revealed with osmium iodide reaction in human and animal epidermis under conditions of hyperpigmentation and depigmentation.
        J Invest Dermatol. 1961; 37: 107-120
        • Zelickson A
        • Mottaz J
        Epidermal dendritic cells.
        Arch Dermatol. 1968; 98: 652-658
        • Al Badri A
        • Foukis A
        • Todd P
        • et al.
        Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo.
        J Pathol. 1993; 169: 203-206
        • Hull S
        • Nutbrown M
        • Pepall L
        • et al.
        Immunohistologic and ultrastructural comparison of the dermal papilla and hair follicle bulb from “active” and “normal” areas of alopecia areata.
        J Invest Dermatol. 1991; 96: 673-681
        • Breathnach A
        An atlas of the ultrastructure of human skin.
        in: Churchill, London1971: 206
        • Lerner A
        Repopulation of pigment cells in patients with vitiligo.
        Arch Dermatol. 1988; 124: 1701-1702
        • Hacker SM
        Common disorders of pigmentation.
        Postgrad Med. 1996; 99: 177-186
        • Goldstein E
        • Haberman HF
        • Menon IA
        • et al.
        Non-psoralen treatment of vitiligo. Part I. Cosmetics, systemic coloring agents, and corticosteroids.
        Int J Dermatol. 1992; 31: 229-236
      1. National Vitiligo Foundation, Inc. Newsletter. 1990;2:5.

        • Lerner A
        • Denton C
        • Fitzpatrick T
        Clinical and experimental studies with 8-methoxypsoralen in vitiligo.
        J Invest Dermatol. 1953; 20: 299-314
        • George W
        • Burks J
        Treatment of vitiligo with psoralen derivatives.
        Arch Dermatol. 1955; 71: 14-18
        • El Mofty A
        A preliminary clinical report on the treatment of leukoderma with Ammi majus Linn.
        J Royal Egypt Med Assoc. 1948; 31: 651-655
        • Fahmy IR
        • Abushady H
        A crystalline principle from Ammi majus L.
        Nature. 1947; 160: 468-469
        • Fahmy IR
        • Abu-Shady H
        Ammi majus Linn. Pharmacognostical study and isolation of crystalline constituent, ammoidin.
        Q J Pharm Pharmacol. 1947; 20: 281
        • Fowlks W
        The chemistry of the psoralens.
        J Invest Dermatol. 1959; 32: 249-253
        • Montgomery D
        Vitiligo treated with finsen light.
        J Cutan Urin Dis. 1904; 22: 17-19
        • Buschke A
        N zur behandlung des vitiligo mit licht.
        Med Klinik. 1907; 33: 983-984
        • Moser E
        Zur behandlung des vitiligo mit lichtbestrahlungen.
        Med Klinik. 1907; 45: 1363
        • Buschke A
        Weitere beobachtungen uber lichtpigment.
        Berl Klin Wochenschr. 1907; 44: 1575-1576
        • Stein R
        Ueber experimentell erzeugtes pigment in vitiligo.
        Arch Derm Syph. 1909; 97: 163-178
        • Kissmeyer A
        Studies on pigment with the dopa-reaction, especially in cases of vitiligo.
        Br J Dermatol. 1920; 32: 156-162
        • Pegum J
        Dissociated depigmentation in vitiligo. Significance and therapeutic implications.
        Br J Dermatol. 1955; 67: 348-350
        • Sidi E
        • Bourgeois-Gavardin J
        Resultats du traitement du vitiligo par l’ “Ammi Majus” Linn.
        Bull Soc Fr Derm Syph. 1951; 58: 490-492
        • Kelly E
        • Pinkus H
        Local application of 8-methoxypsoralen in vitiligo.
        J Invest Dermatol. 1955; 25: 453-456
        • Kanof N
        Melanin formation in vitiliginous skin under influence of external applications of 8-methoxypsoralen.
        J Invest Dermatol. 1955; 24: 5-10
        • Becker S
        Psoralen phototherapeutic agents.
        JAMA. 1967; 202: 120-122
        • Buck H
        • Magnus I
        • Porter A
        The action spectrum of 8-methoxypsoralen for erythema in human skin.
        Br J Dermatol. 1960; 72: 249-255
        • Pathak M
        • Fellman J
        Activating and fluorescent wave-lengths of furocoumarins: psoralens.
        Nature. 1990; 185: 382-383
        • Pathak M
        Mechanism of psoralen photosensitization and in vivo biological action spectrum of 8-methoxypsoralen.
        J Invest Dermatol. 1962; 37: 397-407
        • Pathak M
        • Fellman J
        • Kaufman K
        The effect of structural alterations on the erythemal activity of furocoumarins: psoralens.
        J Invest Dermatol. 1960; 135: 165-183
        • Stegmair O
        The use of methoxsalen in sun tanning.
        J Invest Dermatol. 1959; 32: 345-350
        • Fulton J
        • Leyden J
        • Papa C
        Treatment of vitiligo with topical methoxsalen and blacklite.
        Arch Dermatol. 1969; 100: 224-229
        • Africk J
        • Fulton J
        Treatment of vitiligo with topical trimethylpsoralen and sunlight.
        Br J Dermatol. 1971; 84: 151-156
        • Parrish J
        • Fitzpatrick T
        • Shea C
        • et al.
        Photochemotherapy of vitiligo.
        Arch Dermatol. 1976; 112: 1531-1534
        • Parrish J
        • Fitzpatrick T
        • Tanenbaum L
        • et al.
        Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.
        N Engl J Med. 1974; 291: 1207-1211
        • Song PS
        • Tapley KJ
        Photochemistry and photobiology of psoralens.
        Photochem Photobiol. 1979; 29: 1177-1197
        • Zaynoun S
        • Mcvittie E
        • Hunter J
        Melanosomal pattern in phototoxic pigmentary responses induced by topical psoralens and other photosensitizers.
        Clin Exp Dermatol. 1977; 2: 243-254
        • Kao C
        • Yu H
        Comparison of the effect of 8-methoxy-psoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro.
        J Invest Dermatol. 1992; 98: 734-740
        • Staricco K
        Amelanotic melanocytes in the outer sheath of the human hair follicle.
        J Invest Dermatol. 1959; 33: 295-297
        • Staricco R
        The melanocytes and the hair follicle.
        J Invest Dermatol. 1960; 35: 185
        • Staricco R
        Mechanism of migration of the melanocytes from the hair follicle into the epidermis following dermabrasion.
        J Invest Dermatol. 1961; 36: 99-104
        • Staricco R
        • Miller-Milinska A
        Activation of the amelanotic melanocytes in the outer root sheath of the hair follicle following ultraviolet rays exposure.
        J Invest Dermatol. 1962; 39: 163
        • Ortonne J
        • Macdonald D
        • Micoud A
        • et al.
        PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultrastructural study.
        Br J Dermatol. 1979; 101: 1-12
        • Ortonne J
        • Schmitt D
        • Thivolet J
        PUVA-induced repigmentation of vitiligo: scanning electron microscopy of hair follicles.
        J Invest Dermatol. 1980; 74: 40-42
        • Cui J
        • Shen L
        • Wang G
        Role of hair follicles in the repigmentation of vitiligo.
        J Invest Dermatol. 1991; 97: 410-416
        • Horikawa T
        • Norris D
        • Johnson TW
        • et al.
        DOPA-negative melanocytes in the outer root sheath of human hair follicles express premelanosomal antigens but not a melanosomal antigen or the melanosome-associated glycoproteins tyrosinase, TRP-1, and TRP-2.
        J Invest Dermatol. 1996; 106: 28-35
        • Halaban R
        • Langdon R
        • Birchall N
        • et al.
        Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes.
        J Cell Biol. 1988; 107: 1611-1619
        • Gordon P
        • Mansur C
        • Gilchrest B
        Regulation of human melanocyte growth, dendricity, and melanization by keratinocyte derived factors.
        J Invest Dermatol. 1989; 92: 565-572
        • Birchall N
        • Orlow S
        • Kuper T
        • et al.
        Interactions between ultraviolet light and interleukin-1 on MSH binding in both mouse melanoma and human squamous carcinoma cells.
        Biochem Biophys Res Commun. 1991; 175: 839-845
        • Morelli J
        • Yoln J
        • Lyons B
        • et al.
        Leukotrienes C4 and D4 as potent mitogens for cultured human neonatal melanocytes.
        J Invest Dermatol. 1989; 93: 719-722
        • Morelli J
        • Kincannon J
        • Yohn J
        • et al.
        Leukotriene C4 and TGF-Alpha are stimulators of human melanocyte migration in vitro.
        J Invest Dermatol. 1992; 98: 290-295
        • Grimes P
        Vitiligo. An overview of therapeutic approaches.
        Dermatol Clin. 1993; 11: 325-338
        • London I
        Evaluation of methoxsalen in the treatment of vitiligo.
        J Invest Dermatol. 1959; 32: 315-317
        • Farah F
        • Kurban A
        • Chaglassian H
        The treatment of vitiligo with psoralens and traimcinolone by mouth.
        Br J Dermatol. 1967; 79: 89-91
        • Ortonne J
        Psoralen therapy in vitiligo.
        Clin Dermatol. 1989; 7: 120-135
        • Grimes PE
        • Minus HR
        • Halder RM
        • et al.
        Vitiligo: racial variations in the response to topical photochemotherapy.
        J Invest Dermatol. 1983; 80: 367
        • Honig B
        • Morison WL
        • Karp D
        Photochemotherapy beyond psoriasis.
        J Am Acad Dermatol. 1994; 31: 775-790
        • Tsukada S
        Treatment of vitiligo.
        Rinsho Derma (Tokyo). 1959; 1: 105
        • Kandil E
        Treatment of localized vitiligo with intradermal injections of triamcinolone acetonide.
        Dermatologica. 1970; 140: 195-206
        • Kandil E
        Vitiligo: response to 0.2% betamethasone 17-valerate in flexible collodion.
        Dermatologica. 1970; 141: 277-281
        • Koopmans-van Dorp B
        • Goldhart-van Duk B
        • Neering H
        • et al.
        Treatment of vitiligo by local application of betamethsone 17-valerate in a dimethyl sulfoxide cream base.
        Dermatologica. 1973; 146: 310-314
        • Kandil E
        Treatment of vitiligo with 0.1% betamethasone 17-valerate in isopropyl alcohol: a double-blind trial.
        Br J Dermatol. 1974; 91: 457-460
        • Kumari J
        Vitiligo treated with topical clobetasol propionate.
        Arch Dermatol. 1984; 120: 631-635
        • Hernandez-Perez E
        Vitiligo treated with ACTH.
        Int Soc Tropic Dermatol. 1979; 18: 578-579
        • Gokhale B
        • Gokhale T
        Corticotrophin and vitiligo (preliminary observations).
        Br J Dermatol. 1976; 95: 329
        • Vasistha LK
        • Singh G
        Vitiligo and intralesional steroids.
        Indian J Med Res. 1979; 69: 308-311
        • Behl P
        Treatment of vitiligo with homologous thin Thiersch’s skin gratis.
        Curr Med Pract. 1964; 8: 218-221
        • Khstala U
        Suction blister device for separation of viable epidermis from dermis.
        J Invest Dermatol. 1968; 50: 129-137
        • Suvanprakorn P
        • Dee-Ananlap S
        • Pongsomboon C
        • et al.
        Melanocyte autologous grafting for treatment of leukoderma.
        J Am Acad Dermatol. 1985; 13: 968-974
        • Koga M
        Epidermal grafting using the tops of suction blisters in the treatment of vitiligo.
        Arch Dermatol. 1988; 124: 1656-1658
        • Suga Y
        • Butt KI
        • Takimoto R
        • et al.
        Successful treatment of vitiligo with PUVA-pigmented autologous epidermal grafting.
        Int J Dermatol. 1996; 35: 518-522
        • Behl P
        Repigmentation of segmental vitiligo by autologous minigrafting.
        J Am Acad Dermatol. 1985; 12: 118-119
        • Bose SK
        Modified Thiersch grafting in stable vitiligo.
        J Dermatol. 1996; 23: 362-364
        • Falabella R
        Treatment of localized vitiligo by autologous minigrafting.
        Arch Dermatol. 1988; 124: 1649-1655
        • Falabella R
        Repigmentation of segmental vitilio by autologous minigrafting.
        J Am Acad Dermatol. 1983; 9: 514-521
        • Falabella R
        • Armnategui A
        • Barona MI
        • Alzate A
        The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation.
        J Am Acad Dermatol. 1995; 32: 228-232
        • Falabella R
        • Escobar C
        • Borrero I
        Transplantation of in vitro–cultured epidermis beating melanocytes for repigmenting vitiligo.
        J Am Acad Dermatol. 1989; 21: 257-264
        • Brysk M
        • Newton R
        • Rajaraman S
        • et al.
        Repigmentation of vitiliginous skin by cultured cells.
        Pigment Cell Res. 1989; 2: 202-207
        • Falabella R
        • Escobar C
        • Borrero I
        Treatment of refractory and stable vitiligo by transplantation of in vitro cultured epidermal autografts bearing melanocytes.
        J Am Acad Dermatol. 1992; 26: 230-236
        • Gilchrest B
        • Vrabel M
        • Flynn E
        • et al.
        Selective cultivation of human melanocytes from newborn and adult epidermis.
        J Invest Dermatol. 1984; 83: 370-376
        • Lerner A
        • Halaban R
        • Klaus S
        • et al.
        Transplantation of human melanocytes.
        J Invest Dermatol. 1987; 89: 219-224
        • Juhlin L
        • Olsson MJ
        Vitiligo.
        Br J Dermatol. 1996; 135: 852
        • Gauthier Y
        • Surleve-Bazeille J
        Autologous grafting with noncultured melanocytes: a simplified method for treatment of depigmented lesions.
        J Am Acad Dermatol. 1992; 26: 191-194
        • Oliver E
        • Schwartz L
        • Warren L
        Occupational leukoderma.
        Arch Dermatol Syph. 1940; 42: 993-1014
        • McNally W
        A depigmentation of the skin.
        Industrial Med. 1939; 8: 405-410
        • Denton D
        • Lerner A
        • Fitzpatrick T
        Inhibition of melanin formation by chemical agents.
        J Invest Dermatol. 1951; 18: 119-135
        • Passi S
        • Nazzaro-Porro M
        Molecular basis of substrate and inhibitory specificity of tyrosinase: phenolic compounds.
        Br J Dermatol. 1981; 104: 659-665
        • Jimbow K
        • Obata H
        • Pathak M
        • et al.
        Mechanism of depigmentation by hydroquinone.
        J Invest Dermatol. 1974; 62: 436-449
        • Rheins LA
        • Young EM
        • Nordlund ML
        • et al.
        Rapid induction of Thy-1 antigenic markers on keratinocytes and epidermal immune cells in the skin of mice following topical treatment with common preservatives used in topical medications and in foods.
        J Invest Dermatol. 1987; 89: 489-494
        • Becker S
        • Spencer M
        Evaluation of monobenzone.
        JAMA. 1962; 180: 279-284
        • Dorsey C
        Dermatitic and pigmentary reactions to monobenzyl ether of hydroquinone.
        Arch Dermatol. 1940; 81: 123-126
        • Riley P
        Hydroxyanisole depigmentation: in-vivo studies.
        J Pathol. 1969; 97: 185-191
        • Mosher D
        • Parrish J
        • Fitzpatrick T
        Monobenzylether of hydroquinone.
        Br J Dermatol. 1977; 97: 669-679
        • Tsuji T
        • Hamada T
        Topically administered fluorouracil in vitiligo.
        Arch Dermatol. 1983; 119: 722-727
        • Szekeres E
        • Morvay M
        Repigmentation of vitiligo macules treated topically with efudix cream.
        Dermatologica. 1985; 171: 55-59
        • Cormane RH
        • Siddiqui AH
        • Nengerman IM
        Photochemotherapy of vitiligo with oral phenylalanine.
        J Invest Dermatol. 1983; 80: 367
        • Cormane R
        • Siddiqui A
        • Westerhof W
        • et al.
        Phenylalanine and UVA light for the treatment of vitiligo.
        Arch Dermatol Res. 1985; 277: 126-130
        • Schulpis CH
        • Antoniou C
        • Michas T
        • et al.
        Phenylalanine plus ultraviolet light: preliminary report of promising treatment for childhood vitiligo.
        Pediatr Dermatol. 1989; 6: 332-335
        • Antiniou C
        • Schulpis H
        • Michas T
        • et al.
        Vitiligo therapy with oral and topical phenylalanine with UVA exposure.
        Int J Dermatol. 1989; 28: 545-547
        • Ryan WL
        • Carver MJ
        Inhibition of antibody synthesis by L-phenylalanine.
        Science. 1964; 43: 479-480
        • Westerhof W
        • Groot I
        • Krieg SR
        • et al.
        Langerhans’ cell population studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation.
        Acta Derm Venereol (Stockh). 1986; 66: 259-274
        • Srinivas C
        • Shenoi S
        • Blachandran C
        Acceleration of repigmentation in vitiligo by topical minocidil in patients on photochemotherapy.
        Int J Dermatol. 1990; 29: 14-15
        • Pattison EM
        Uveomeningoencephalitic syndrome (Vogt-Koyanagi-Harada).
        Arch Neurol. 1965; 12: 197-205
        • Snyder DA
        • Tessler HH
        Vogt-Koyanagi-Harada syndrome.
        Am J Ophthalmol. 1980; 90: 69-75
        • Buc M
        • Busova B
        • Hegyi E
        • et al.
        Vitiligo is associated with HLA-A2 and HLA-Dw7 in the Slovak populations.
        Folia Biologica. 1996; 42: 23-25
        • Dunston G
        • Halder R
        Vitiligo is associated with HLA-DR4 in black patients: a preliminary report.
        Arch Dermatol. 1990; 126: 56-60
        • Finco O
        • Cuccia M
        • Matinetti M
        • et al.
        Age of onset in vitiligo: relationship with HLA seratypes.
        Clin Genet. 1991; 39: 48-54
        • Foley L
        • Lowe N
        • Misheloff E
        • et al.
        Association of HLA-DR4 with vitiligo.
        J Am Acad Dermatol. 1983; 8: 38-40
        • Metzker A
        • Zamir R
        • Gazit E
        • et al.
        Vitiligo and HLA system.
        Dermatologica. 1980; 160: 100-105
        • Orecchia G
        • Perfeti P
        • Malagoli F
        • et al.
        Vitiligo is associated with a significant increase in HLA-A30, Cw6 and DQw3 and a decrease in C4AQ0 in northern Italian patients.
        Dermatology. 1992; 185: 123-127
        • Poloy A
        • Tibor L
        • Kramer J
        • et al.
        HLA-DR1 is associated with vitiligo.
        Immunol Lett. 1991; 27: 59-62
        • Venneker G
        • Westerhof W
        • deVries I
        • et al.
        Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo.
        J Invest Dermatol. 1992; 99: 853-858
        • Davis JL
        • Mittal KK
        • Freidlin V
        • et al.
        HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia.
        Ophthalmology. 1990; 97: 1137-1142
        • Zhao M
        • Jiang Y
        • Abrahams IW
        Association of HLA antigens with Vogt-Koyanagi-Harada syndrome in a Han Chinese population.
        Arch Ophthalmol. 1991; 109: 368-370